Human papillomavirus infection and non-oropharyngeal head and neck cancers: an umbrella review of meta-analysis

Human papillomavirus infection and the risk of cancer at specific sites other than anogenital tract and oropharyngeal region: an umbrella review

“…Our findings were highly consistent with the suggestion from the IARC 2007, indicating the strong evidence for the carcinogenicity of HPV in oral. 22 Recently, an umbrella review with 15 meta-analyses reported highly suggestive evidence that the infection with HPV was associated with a greater risk of oral cavity cancer, 95 which was generally in line with our findings. Likewise, in a recent case–control study, HPV seropositivity increased an overall risk of OSCC and existed a strong combined effect with smoking and alcohol.…”

A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The “ALARM” study

“…Evidence to date suggests that HPV prevalence is higher among OPC than other HN subsites. [5][6][7]36,135,136 Importantly, though the prognostic impact of HPV status in non-OPC HNC is unclear, [24][25][26] HPV infection is an established prognostic indicator of treatment outcome in OPC. [14][15][16] Hence, findings of the overall HPV prevalence herein should be interpreted in the context of the contribution of OPC, while special attention should also be drawn to HPV+ estimates within this highly relevant HNC subgroup.…”

“…In single-continent HNC studies conducted in Northern America (n = 34), the prevalence of HPV ranged from 8.3% to 100.0%; in Europe (n = 29) from 3.1% to 75.9%; in Eastern Asia (n = 3) from 10.3% to 33.3%. The mean (and pooled) prevalence of HPV among single-continent studies conducted in Northern America was 46.0% (42.1%), followed by 24 ). In studies conducted in multiple continents (n = 15) the prevalence of HPV ranged from 2.9% to 30.4%, and the mean (and pooled) prevalence of HPV was 19.8% (18.4%).…”

“…19,20 Testing of p16 is recommended by the European Head and Neck Society/European Society for Medical Oncology/European Society for Radiotherapy and Oncology, the National Comprehensive Cancer Network, the College of American Pathologists, and the American Society of Clinical Oncology guidelines as a surrogate HPV biomarker in OPSCC management. 12,13,[21][22][23] Nevertheless, given than the prognostic impact of HPV in other HNC subsites is unclear, [24][25][26] routine examination for HPV presence for other HNC types is not warranted. 21 For patients with limited or early-stage HNSCC, current treatment modalities are potentially curative, while for recurrent and/or metastatic (RM) HNSCC, treatment is complex, prognosis is poor, and the burden on quality of life and productivity can be substantial.…”

“…Testing of p16 is recommended by the European Head and Neck Society/European Society for Medical Oncology/European Society for Radiotherapy and Oncology, the National Comprehensive Cancer Network, the College of American Pathologists, and the American Society of Clinical Oncology guidelines as a surrogate HPV biomarker in OPSCC management 12,13,21–23 . Nevertheless, given than the prognostic impact of HPV in other HNC subsites is unclear, 24–26 routine examination for HPV presence for other HNC types is not warranted 21 …”